A Study of AT-02 in Subjects With Systemic Amyloidosis.

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(4 sites)

United States

Kansas City, Kansas City, Kansas

Cleveland Clinic, Cleveland, Ohio

OHSU (Oregon Health & Science University), Portland, Oregon

Penn Presbyterian Medical Center, Philadelphia, Pennsylvania